School of Basic Medicine, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China.
Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.
Sci Rep. 2021 Aug 30;11(1):17381. doi: 10.1038/s41598-021-96195-w.
Cancer patients are more susceptible to SARS-CoV-2 infection and generally have higher mortality rate. Anti-SARS-CoV-2 IgG is an important consideration for the patients in this COVID-19 pandemic. Recent researches suggested the rapid decay of anti-SARS-CoV-2 antibodies in the general population, but the decline rate of the antibodies in cancer patients was unknown. In this observational study, we reported the clinical features of the 53 cancer patients infected by SARS-CoV-2 from Wuhan, China and tracked the presence of anti-SARS-CoV-2 antibodies in the patients for more than 12 months. We found the duration (days) of anti-SARS-CoV-2 IgG in the patients was significant longer in chemotherapy (mean: 175; range: 75 to 315) and radiotherapy groups (mean: 168; range: 85 to 265) than in non-chemo- or radio-therapy group (mean: 58; range: 21 to 123) after their recovery from COVID-19. We also used single-cell RNA sequencing to track the immunologic changes in a representative patient recovered from COVID-19 and found that CD8 + effective T cells, memory B cells and plasma cells were persistently activated in the patient undergoing chemotherapy. Together, our findings show that chemotherapy and radiotherapy might be beneficial to extend the duration of anti-SARS-CoV-2 IgG.
癌症患者更容易感染 SARS-CoV-2，且一般死亡率更高。抗 SARS-CoV-2 IgG 是 COVID-19 大流行期间癌症患者的重要考虑因素。最近的研究表明，普通人群中抗 SARS-CoV-2 抗体迅速衰减，但癌症患者的抗体衰减率尚不清楚。在这项观察性研究中，我们报告了来自中国武汉的 53 名 SARS-CoV-2 感染癌症患者的临床特征，并对这些患者的抗 SARS-CoV-2 抗体进行了超过 12 个月的跟踪检测。我们发现，与非化疗或放疗组（中位时间：58 天，范围：21-123 天）相比，在 COVID-19 康复后，接受化疗（中位时间：175 天，范围：75-315 天）和放疗（中位时间：168 天，范围：85-265 天）的癌症患者的抗 SARS-CoV-2 IgG 持续时间更长。我们还使用单细胞 RNA 测序来跟踪一名 COVID-19 康复患者的免疫变化，发现接受化疗的患者体内的 CD8+有效 T 细胞、记忆 B 细胞和浆细胞持续激活。综上，我们的研究结果表明，化疗和放疗可能有助于延长抗 SARS-CoV-2 IgG 的持续时间。
